What is PBYI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PBYI?

P/E (TTM) is 19.93 and 52-week range is $4.58 to $10.10 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PBYI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PBYI?

The company profile lists revenue (TTM) near $224M, net income (TTM) near $26M, EPS (TTM) near $0.52 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Puma Biotechnology Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Los Angeles, California, US, 50.9M shares outstanding, ISIN US74587V1070 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 179 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Employees

179

Website

www.pumabiotechnology.com/

IPO

2012-03-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)